In environments with systemic failures, like healthcare in Nigeria, a product for a single pain point is ineffective. A successful solution must address interconnected issues like supply chain integrity, user financing, and logistics simultaneously, treating the entire value chain as the product.

Treat patient initiatives not as single-use projects tied to a drug launch, but as long-term, sustainable assets. Design programs with an eye toward future applicability for other drugs, therapeutic areas, or geographies. This approach maximizes the return on investment and creates an institutional capability.

Many therapies fail to meet real-world expectations because they are designed for the lab, not life. Innovations focus on clinical efficacy, which drives only 20% of health outcomes, while ignoring the 80% driven by crucial psychological, social, and environmental factors.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.

Malaria expert James Tabenderana notes that research is adopted much faster when led by national researchers. In the Sahel, studies on malaria chemoprevention were quickly implemented because local researchers, with their existing trust and relationships with ministry of health officials, could effectively bridge the gap between evidence and policy.

When foreign aid agencies bypass national governments to work directly with NGOs, they may ensure short-term efficiency but inadvertently weaken the country's own public systems (e.g., healthcare). This creates a patchwork of services that lacks long-term sustainability and scalability, a major unseen negative consequence.

Implementing technology is just the start. Most healthcare organizations fail by abandoning projects post-launch. True adoption requires a continuous feedback loop with end-users like doctors and nurses to evaluate use cases, identify pain points, and iteratively improve the solution.

Most drug launch failures stem from three core mistakes: engaging medical affairs too late to educate physicians pre-launch, having a flawed payer and reimbursement strategy, and neglecting to build a robust plan for generating and publishing real-world evidence to support the drug's value proposition.